Physician profile
David B Kaye
NPI 1124180518
$567.39
in general payments reported to CMS, 2019-2025
13 companies · $39.40 in 2025
The $39.40 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.58 · 2020: $39.14 · 2021: $310 · 2022: $34.99 · 2023: $90.10 · 2024: $22.69 · 2025: $39.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $134 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $134.35 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $201.13 | 2021 | |
| Horizon Therapeutics Plc | $73.03 | 2021-2023 | Tepezza |
| Mallinckrodt Hospital Products INC. | $49.13 | 2021 | |
| Amgen INC. | $48.59 | 2024-2025 | Tepezza |
| Synergeyes, INC. | $30.58 | 2019 | |
| Alcon Vision LLC | $29.97 | 2020-2021 | |
| Eyepoint US, INC. | $24.25 | 2020 | |
| Alimera Sciences, INC. | $22.35 | 2023 | Iluvien |
| Dompe US, INC. | $20.35 | 2021 | |
| Oyster Point Pharma, INC. | $19.85 | 2022 | |
| Bausch & Lomb Americas INC. | $17.84 | 2023 | Miebo |
| Abbvie INC. | $16.82 | 2023 | |
| Tarsus Pharmaceuticals, INC. | $13.50 | 2025 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kaye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.